Side-by-side · Research reference
OvagenvsPE 22-28
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
ATheoreticalHUMAN-REVIEWED2/42 cited
BAnimal-StrongHUMAN-REVIEWED16/47 cited
Ovagen
Khavinson Bioregulator · Ovarian
OvarianTarget tissue
Di/Tri-peptidePeptide length
AnimalEvidence tier
Oral / SQ · Protocol varies
PE 22-28
TREK-1 Antagonist · Pre-Clinical
IP · SQ · Once Daily (animal models)Djillani 2017Pietri 2019
01Mechanism of Action
Parameter
Ovagen
PE 22-28
Primary target
Ovarian tissue chromatin complexes
TREK-1 two-pore-domain potassium channelDjillani 2017Ma 2020
Pathway
Tissue-specific peptide → Nuclear chromatin binding → Gene expression modulation → Cellular differentiation
TREK-1 channel blockade → Neuronal membrane depolarisation → Enhanced hippocampal excitability → Increased neuroplasticity
Downstream effect
Proposed ovarian functional support, fertility regulation, hormonal homeostasis restoration
Antidepressant-like activity in forced swim test and tail suspension test; reduced A1-like reactive astrocyte activation; neuroprotection via NF-κB pathway modulationDjillani 2017Cong 2023Wu 2021
Feedback intact?
Presumed physiological — Khavinson peptides described as regulatory, not replacement
N/A — direct ion channel blockade; not receptor-mediated endocrine axis
Origin
Extracted from bovine/porcine ovarian tissue; short synthetic peptides (2–4 amino acids)
Synthetic truncation of spadin (PE 12-28), itself derived from the sortilin propeptide C-terminus. Residues 22-28: Val-Val-Arg-Gly-Trp-Leu-Arg.Djillani 2017Mazella 2018
Antibody development
—
Not reported in animal studies
02Dosage Protocols
Parameter
Ovagen
PE 22-28
Standard dose
10–20 mg / day (oral) or 1–2 mg SQ
Extrapolated from Khavinson-school protocols; no ovagen-specific PubMed dose studies.
—
Frequency
Once daily or cyclical (10–20 days per month)
Cyclical protocols common in Khavinson bioregulator tradition.
Once daily
Sustained antidepressant effect over 7+ days.
Evidence basis
Theoretical / Russian-tradition
Multiple rodent RCTs; behavioral + electrophysiology endpointsDjillani 2017Qi 2018Wu 2021
Duration
4–12 weeks per cycle
Khavinson protocols typically 1–3 months; repeat cycles as needed.
—
Route
Oral (capsule) or subcutaneous
Oral absorption assumed for short peptides; SQ route mirrors other Khavinson bioregulators.
—
Animal dose (antidepressant)
—
0.3–3 µg/kg IP
Effective in forced swim test, tail suspension test, CUMS models.
Animal dose (neuroprotection)
—
0.03 µg/kg IPPietri 2019
Low-dose TREK-1 activation post-stroke for 7 days, then high-dose blockade.
Onset (animal)
—
Within hours (acute); full effect 4–7 days
Comparison to fluoxetine
—
PE 22-28 outperforms fluoxetine in CUMS-sensitive rats by day 7
Chronic administration shows superior long-term efficacy.
Human equivalent (extrapolated)
—
Not established — no clinical trials
Allometric scaling from rodent data unavailable.
04Side Effects & Safety
Parameter
Ovagen
PE 22-28
Reported adverse events
None documented in indexed literature
—
Theoretical hormonal effects
Ovarian stimulation — monitor for estrogen-sensitive conditions
—
Injection site reaction
Possible mild erythema (SQ route)
—
Long-term safety
Unknown — no PubMed-indexed RCTs
Unknown — longest animal study 28 days
Toxicity (animal)
—
No adverse effects reported at therapeutic doses
Cardiovascular (theoretical)
—
TREK-1 expressed in cardiac tissue; arrhythmia risk unclear
Weight change
—
Not reported in animal studies
Neurological
—
No seizures or behavioral abnormalities noted
Absolute Contraindications
Ovagen
- ·Active hormone-sensitive malignancy (breast, ovarian, endometrial)
- ·Pregnancy
PE 22-28
- ·Human use — no clinical safety data available
Relative Contraindications
Ovagen
- ·History of estrogen-sensitive tumors (monitor)
- ·Polycystic ovary syndrome (PCOS) — theoretical ovarian hyperstimulation risk
- ·Endometriosis or fibroids (estrogen-responsive conditions)
PE 22-28
- ·Cardiac arrhythmia or channelopathy (theoretical TREK-1 cardiac role)
05Administration Protocol
Parameter
Ovagen
PE 22-28
1. Oral route
Typical dose: 10–20 mg once daily. Capsule form — taken on empty stomach, 20–30 min before meals. Khavinson tradition suggests morning administration.
Dissolved in sterile saline or vehicle. Intraperitoneal injection, 0.3–3 µg/kg body weight. Once daily administration in rodent behavioral studies.
2. Subcutaneous route
1–2 mg per injection. Reconstitute lyophilised powder with sterile water if required. Inject into abdomen or thigh; rotate sites.
Shorter peptide length (7 AA) confers improved plasma stability vs 17-AA spadin. Exact storage conditions not detailed in published protocols.Djillani 2017
3. Cyclical protocol
Common pattern: 10–20 days on, 10 days off. Aligns with menstrual cycle phases in some protocols. Repeat cycles for 2–3 months, then assess.
Enhanced CNS bioavailability vs full spadin, likely due to smaller size. Mechanism (passive diffusion vs active transport) not fully characterized.
4. Storage
Lyophilised: room temperature, light-protected. Reconstituted: refrigerate 2–8 °C, use within 7–14 days.
Not established — peptide synthesis methods for research use only. No pharmaceutical-grade formulation available.